Day: November 13, 2025

Accelsius recently secured strategic investment from Johnson Controls and introduced its NeuCool® MR250 system; pipeline of opportunities now exceeds $1 billion AeroFlexx delivered 5th consecutive quarter of revenue generation with growing customer pipeline in U.S. and Europe Refinity on track to demonstrate pilot scale and finalize initial site selection for first plant by year-end ORLANDO, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure”), an industrial growth conglomerate, today announced financial results for the quarter ended September 30, 2025. “Innventure’s momentum continued in the third quarter, driven by meaningful execution across our operating companies. Accelsius, AeroFlexx, and Refinity each advanced key commercial and technical milestones, reinforcing our belief that Innventure...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025, and highlighted recent achievements. “As we continue to advance our pipeline, we are entering an important period for Alumis. Our teams have been working diligently, and we are eagerly anticipating key milestones ahead – with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by topline Phase 2b LUMUS data in systemic lupus erythematosus (SLE) in the third quarter,” said Martin Babler, President and Chief Executive...

MARKHAM, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2025. HighlightsAverage Same Property Occupancy in retirement segment up 230 basis points (“bps”) year over year, and 200 bps quarter over quarter, to 94.1% in Q3 2025, further increasing to 94.7% in October 2025 Same Property Net Operating Income (“NOI”), excluding One-Time Items, up 9.7% year-over-year to $46.4 million in Q3 2025 Retirement Segment up 13.2% year-over-year in Q3 2025 Long-Term Care (“LTC”) Segment up 6.7% year-over year in Q3 2025Adjusted Funds from Operations (“AFFO”), excluding One-Time Items, increased by 36.1% year-over-year, or by 12.0% on a per share basis, in Q3 2025 AFFO Payout Ratio, excluding...

AUSTIN, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the first quarter of fiscal year 2026, which ended September 30, 2025. Financial Highlights & Recent Developments   Revenue increased to $297 thousand or 35% in the first quarter of fiscal year 2026 as compared to the fourth quarter of fiscal year 2025 as Astrotech’s subsidiary, 1st Detect, had more grant revenue and sold more consumables compared to prior quarter. As of September 30, 2025, the Company has deployed the TRACER 1000 in approximately 34 locations in 16 countries across the United States, Europe and Asia. On August 18, 2025, the Company announced that the Board of Directors of the Company had appointed Mr. Nihanth Badugu as Chief Operating Officer of the Company...

Transformational Quarter Strengthens Balance Sheet, Launches LINK-Anchored Digital Asset Treasury, and Positions Caliber on Path to Adjusted EBITDA Profitability SCOTTSDALE, Ariz., Nov. 13, 2025 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today reported results for the third quarter ended on September 30, 2025. Third Quarter 2025 HighlightsRaised more than $30.0 million through common and preferred equity, strengthening Caliber’s balance sheet and liquidity. Launched Caliber’s Digital Asset Treasury (“DAT”) anchored in Chainlink (LINK) tokens, expanding the Company’s business into digital asset management alongside its core Private Equity Real Estate (PERE) platform.Third Quarter 2025 Platform Financial Results (compared to Third Quarter 2024)Platform revenue...

Record Q4 and Full Year Revenue & PLOStrong Growth in Diluted EPS & Adjusted EBITDA AUSTIN, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — EZCORP, Inc. (NASDAQ: EZPW), a leading provider of pawn transactions in the United States and Latin America, today announced results for its fourth quarter and full year ended September 30, 2025. Unless otherwise noted, all amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”) and comparisons shown are to the same period in the prior year. FOURTH QUARTER HIGHLIGHTSNet income increased 76% to $26.7 million. On an adjusted basis1, net income increased 45% to $26.8 million. Diluted earnings per share (EPS) increased 62% to $0.34. On an adjusted basis1, diluted earnings per share increased 36% to $0.34. Adjusted EBITDA increased 33% to $47.9 million. Total...

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC’s transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiation of registrational trials for both programs in 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR), the leading blockchain-native capital marketplace for the origination, funding, sale and trading of tokenized assets, today announced financial results for the quarter ended September 30, 2025.  “We recently completed our successful initial public offering and are pleased to report a strong first quarter as a public company. The continued success of Figure’s marketplace approach to tokenized consumer loan origination drove significant growth in earnings, with Net Income increasing 227% year-over-year while also achieving an Adjusted EBITDA margin of 55%, underscoring the scalability of our blockchain-based model. Alongside margin expansion, we delivered solid performance across our key metrics, consumer loan marketplace volume, Adjusted Net Revenue,...

Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects Cash, cash equivalents and marketable securities of $134.4 million as of September 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon...